| |
| |
|
| Insider
Information: |
George Simeon |
| Relationship: |
|
| City: |
Conshohocken |
| State: |
PA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
12,573,746 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$41,983,927 |
|
|
| Total
Shares |
12,573,746 |
|
|
| Total
Value |
$41,983,927 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 123.7%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Genocea Biosciences, Inc. |
GNCA |
Director |
2014-02-10 |
0 |
2014-02-10 |
1,671,667 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
|
2016-10-24 |
0 |
2024-02-27 |
769,196 |
Premium* |
|
|
Principia Biopharma Inc |
PRNB |
Director |
2018-09-18 |
0 |
2020-09-28 |
0 |
Premium* |
|
|
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2019-04-22 |
0 |
2022-08-17 |
0 |
Premium* |
|
|
Design Therapeutics, Inc. |
DSGN |
Director, 10% Owner |
2021-03-30 |
0 |
2022-12-20 |
6,526,476 |
Premium* |
|
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2023-11-27 |
1,821,415 |
Premium* |
|
|
Nkarta, Inc. |
NKTX |
|
2022-04-28 |
0 |
2024-03-27 |
1,784,992 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
23 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NKTX |
Nkarta, Inc. |
|
– • – |
2024-03-27 |
4 |
B |
$10.00 |
$20,000,000 |
I/I |
2,000,000 |
451,659 |
0.01 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
|
– • – |
2024-02-27 |
4 |
A |
$71.50 |
$74,999,997 |
I/I |
1,048,951 |
769,196 |
0 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
10% Owner |
– – • |
2023-11-27 |
4 |
S |
$0.61 |
$369,457 |
I/I |
(609,163) |
1,821,415 |
0 |
- |
|
| DSGN |
Design Therapeutics, Inc. |
Director |
– • • |
2022-12-20 |
4 |
B |
$8.14 |
$325,432 |
I/I |
40,000 |
6,526,476 |
2.25 |
- |
|
| DSGN |
Design Therapeutics, Inc. |
Director |
– • • |
2022-12-19 |
4 |
B |
$8.63 |
$3,108,096 |
I/I |
360,000 |
6,486,476 |
2.25 |
- |
|
| DSGN |
Design Therapeutics, Inc. |
Director |
– • • |
2022-12-16 |
4 |
B |
$8.28 |
$4,140,550 |
I/I |
500,000 |
6,126,476 |
2.25 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2022-08-17 |
4 |
D |
$76.00 |
$171,278,160 |
I/I |
(2,253,660) |
0 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Director |
– • – |
2022-04-28 |
4 |
B |
$15.00 |
$19,999,995 |
I/I |
1,333,333 |
666,666 |
2.1 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
10% Owner |
– – • |
2021-08-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,822,114 |
|
- |
|
| DSGN |
Design Therapeutics, Inc. |
Director |
– • • |
2021-03-30 |
4 |
B |
$20.00 |
$5,000,000 |
I/I |
250,000 |
5,626,476 |
2.25 |
- |
|
| DSGN |
Design Therapeutics, Inc. |
Director |
– • • |
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
5,376,476 |
5,376,476 |
0 |
- |
|
| PRNB |
Principia Biopharma Inc |
Director |
– • – |
2020-09-28 |
4 |
D |
$100.00 |
$298,285,500 |
I/I |
(2,982,855) |
0 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2020-05-21 |
4 |
B |
$60.00 |
$4,999,980 |
I/I |
83,333 |
2,253,660 |
2.1 |
% |
|
| PRNB |
Principia Biopharma Inc |
Director |
– • – |
2019-10-18 |
4 |
B |
$28.00 |
$9,999,976 |
I/I |
357,142 |
2,982,855 |
2.1 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2019-09-10 |
4 |
B |
$45.00 |
$7,999,965 |
I/I |
177,777 |
2,170,327 |
2.1 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2019-04-22 |
4 |
B |
$18.00 |
$5,850,000 |
I/I |
325,000 |
1,992,550 |
2.1 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2019-04-22 |
4 |
A |
$0.00 |
$0 |
I/I |
1,667,550 |
1,667,550 |
0 |
- |
|
| PRNB |
Principia Biopharma Inc |
Director |
– • • |
2018-09-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,355,713 |
2,355,713 |
0 |
- |
|
| PRNB |
Principia Biopharma Inc |
Director |
– • • |
2018-09-18 |
4 |
B |
$17.00 |
$4,590,000 |
I/I |
270,000 |
2,625,713 |
2.25 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2016-10-24 |
4 |
B |
$14.00 |
$931,000 |
I/I |
66,500 |
3,220,627 |
2.1 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,154,127 |
3,154,127 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
Director |
– • – |
2014-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
1,527,894 |
1,671,667 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
Director |
– • – |
2014-02-10 |
4 |
B |
$12.00 |
$1,725,276 |
I/I |
143,773 |
143,773 |
2.1 |
- |
|
23 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
